Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system-Reference-Cited by-同舟云学术

Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system

Published:2021-11 Issue:48 Volume:39 Page:7066-7073
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Chapin-Bardales Johanna^ORCID,Myers Tanya^ORCID,Gee Julianne,Shay David K.,Marquez Paige,Baggs James,Zhang Bicheng^ORCID,Licata Charles,Shimabukuro Tom T.

Funder

Centers for Disease Control and Prevention

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference28 articles.

1. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020;Oliver;MMWR Morb Mortal Wkly Rep,2020

2. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020;Oliver;MMWR Morb Mortal Wkly Rep,2021

3. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine;Polack;N Engl J Med,2020

4. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine;Baden;N Engl J Med,2021

5. Centers for Disease Control and Prevention. V-safe active surveillance for COVID-19 vaccine safety protocol. January, 28 2021, version 2. https://www.cdc.gov/vaccinesafety/pdf/V-safe-Protocol-508.pdf; [accessed April 14, 2021].

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies;Journal of Experimental Medicine;2024-09-05

2. HIV BG505 SOSIP.664 trimer with 3M-052-AF/alum induces human autologous tier-2 neutralizing antibodies;2024-05-09

3. An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial;Nature Medicine;2024-04-18

4. COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign;Cureus;2024-01-24

5. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial;The Lancet Respiratory Medicine;2023-11